Annals of Oncology

in this issue
pp. 195-195(1)

The quest for the bony Grail of detecting circulating tumour cells in patients with prostate cancer
pp. 197-199(3)
Authors: Massard, C.; Chauchereau, A.; Fizazi, K.

Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor
pp. 200-203(4)
Author: Lvy, B. I.

The emerging epidemic of environmental cancers in developing countries
pp. 205-212(8)
Authors: Vineis, P.; Xun, W.

Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
pp. 213-226(14)
Authors: Pantaleo, M. A.; Nannini, M.; Maleddu, A.; Fanti, S.; Nanni, C.; Boschi, S.; Lodi, F.; Nicoletti, G.; Landuzzi, L.; Lollini, P. L.; Biasco, G.

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
pp. 227-230(4)
Authors: Scartozzi, M.; Galizia, E.; Chiorrini, S.; Giampieri, R.; Berardi, R.; Pierantoni, C.; Cascinu, S.

Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis
pp. 231-238(8)
Authors: Bollschweiler, E.; Metzger, R.; Drebber, U.; Baldus, S.; Vallbhmer, D.; Kocher, M.; Hlscher, A. H.

A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer
pp. 239-243(5)
Authors: Uwagawa, T.; Misawa, T.; Sakamoto, T.; Ito, R.; Gocho, T.; Shiba, H.; Wakiyama, S.; Hirohara, S.; Sadaoka, S.; Yanaga, K.

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
pp. 244-250(7)
Authors: Cunningham, D.; Sirohi, B.; Pluzanska, A.; Utracka-Hutka, B.; Zaluski, J.; Glynne-Jones, R.; Koralewski, P.; Bridgewater, J.; Mainwaring, P.; Wasan, H.; Wang, J.-Y.; Szczylik, C.; Clingan, P.; Chan, R. T. T.; Tabah-Fisch, I.; Cassidy, J.

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
pp. 251-257(7)
Authors: Aranda, E.; Valladares, M.; Martinez-Villacampa, M.; Benavides, M.; Gomez, A.; Massutti, B.; Marcuello, E.; Constenla, M.; Cmara, J. C.; Carrato, A.; Dueas, R.; Reboredo, M.; Navarro, M.; Daz-Rubio, E.

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancercomparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial
pp. 258-264(7)
Authors: Schmidt, M.; Victor, A.; Bratzel, D.; Boehm, D.; Cotarelo, C.; Lebrecht, A.; Siggelkow, W.; Hengstler, J. G.; Elser, A.; Gehrmann, M.; Lehr, H. -A.; Koelbl, H.; von Minckwitz, G.; Harbeck, N.; Thomssen, C.

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer
pp. 265-271(7)
Authors: Andreetta, C.; Puppin, C.; Minisini, A.; Valent, F.; Pegolo, E.; Damante, G.; Di Loreto, C.; Pizzolitto, S.; Pandolfi, M.; Fasola, G.; Piga, A.; Puglisi, F.

Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
pp. 272-277(6)
Authors: Chang, H.; Rha, S. Y.; Jeung, H. -C.; Im, C. -K.; Ahn, J. B.; Kwon, W. S.; Yoo, N. C.; Roh, J. K.; Chung, H. C.

Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial
pp. 278-285(8)
Authors: Maniadakis, N.; Dafni, U.; Fragoulakis, V.; Grimani, I.; Galani, E.; Fragkoulidi, A.; Fountzilas, G.

The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
pp. 286-293(8)
Authors: Oksefjell, H.; Sandstad, B.; Trop, C.

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
pp. 294-297(4)
Authors: Prat, A.; Parera, M.; Adamo, B.; Peralta, S.; Perez-Benavente, M. A.; Garcia, A.; Gil-Moreno, A.; Martinez-Palones, J. M.; Baselga, J.; del Campo, J. M.

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
pp. 298-304(7)
Authors: Cappuzzo, F.; Jnne, P. A.; Skokan, M.; Finocchiaro, G.; Rossi, E.; Ligorio, C.; Zucali, P. A.; Terracciano, L.; Toschi, L.; Roncalli, M.; Destro, A.; Incarbone, M.; Alloisio, M.; Santoro, A.; Varella-Garcia, M.

Detection of circulating tumor cells in patients with urothelial cancer
pp. 305-308(4)
Authors: Gallagher, D. J.; Milowsky, M. I.; Ishill, N.; Trout, A.; Boyle, M. G.; Riches, J.; Fleisher, M.; Bajorin, D. F.

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens
pp. 309-318(10)
Authors: Han, H. S.; Escaln, M. P.; Hsiao, B.; Serafini, A.; Lossos, I. S.

High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
pp. 319-325(7)
Authors: Illerhaus, G.; Marks, R.; Mller, F.; Ihorst, G.; Feuerhake, F.; Deckert, M.; Ostertag, C.; Finke, J.

Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients
pp. 326-330(5)
Authors: Valencak, J.; Weihsengruber, F.; Rappersberger, K.; Trautinger, F.; Chott, A.; Streubel, B.; Muellauer, L.; Der-Petrossian, M.; Jonak, C.; Binder, M.; Raderer, M.

Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome
pp. 331-336(6)
Authors: Van den Wyngaert, T.; Claeys, T.; Huizing, M. T.; Vermorken, J. B.; Fossion, E.

Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients
pp. 337-342(6)
Authors: Derikx, J. P. M.; Blijlevens, N. M. A.; Donnelly, J. P.; Fujii, H.; Kanda, T.; van Bijnen, A. A.; Heineman, E.; Buurman, W. A.

Trends in quality of end-of-life care for Taiwanese cancer patients who died in 20002006
pp. 343-348(6)
Authors: Tang, S. T.; Wu, S.-C.; Hung, Y.-N.; Huang, E.-W.; Chen, J.-S.; Liu, T.-W.

Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience
pp. 349-352(4)
Authors: Galligioni, E.; Berloffa, F.; Caffo, O.; Tonazzolli, G.; Ambrosini, G.; Valduga, F.; Eccher, C.; Ferro, A.; Forti, S.

The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma
pp. 353-357(5)
Authors: Polesel, J.; Zucchetto, A.; Montella, M.; Dal Maso, L.; Crispo, A.; La Vecchia, C.; Serraino, D.; Franceschi, S.; Talamini, R.

Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based casecontrol study
pp. 358-364(7)
Authors: Koomen, E. R.; Joosse, A.; Herings, R. M. C.; Casparie, M. K.; Guchelaar, H. J.; Nijsten, T.

Cancer in adolescents and young adults in north Netherlands (19892003): increased incidence, stable survival and high incidence of second primary tumours
pp. 365-373(9)
Authors: van Gaal, J. C.; Bastiaannet, E.; Schaapveld, M.; Otter, R.; Kluin-Nelemans, J. C.; de Bont, E. S. J. M.; van der Graaf, W. T. A.

Vitamin D intake and breast cancer risk: a casecontrol study in Italy
pp. 374-378(5)
Authors: Rossi, M.; McLaughlin, J. K.; Lagiou, P.; Bosetti, C.; Talamini, R.; Lipworth, L.; Giacosa, A.; Montella, M.; Franceschi, S.; Negri, E.; La Vecchia, C.

The length of consent documents in oncological trials is doubled in twenty years
pp. 379-385(7)
Authors: Berger, O.; Grnberg, B. H.; Sand, K.; Kaasa, S.; Loge, J. H.

Sorafenib is active on lung metastases from synovial sarcoma
pp. 386-387(2)
Authors: Basso, U.; Brunello, A.; Bertuzzi, A.; Santoro, A.

Breast cancer in women younger than 25: clinicopathological features and prognostic factors
pp. 387-389(3)
Authors: Yao, S.; Xu, B.; Ma, F.; Liao, Y.; Fan, Y.

Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma
pp. 389-390(2)
Authors: Brizzi, M. P.; Sculli, C. M.; Ragni, F.; Porpiglia, F.; Tampellini, M.; Gorzegno, G.; Priola, A. M.; Dogliotti, L.; Berruti, A.

Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study
pp. 390-392(3)
Authors: Kim, S. J.; Kim, K.; Kim, B. S.; Suh, C.; Huh, J.; Ko, Y. H.; Kim, W. S.

Treatment of hemodialyzed patient with sunitinib
pp. 392-393(2)
Authors: Reckova, M.; Kakalejcik, M.; Beniak, J.

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
pp. 393-394(2)
Authors: Bono, P.; Elfving, H.; Utriainen, T.; sterlund, P.; Saarto, T.; Alanko, T.; Joensuu, H.

Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxelcisplatin5-fluorouracil regimen
pp. 394-395(2)
Authors: Bitik, B.; Kalpakci, Y.; Altan, E.; Dogan, E.; Altundag, K.

Stopping a trial early in oncology: for patients or for industry?
pp. 395-396(2)
Authors: Bradbury, P.; Meyer, R.; Pater, J.; Tu, D.; Seymour, L.; Shepherd, L.; Eisenhauer, E.